Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P230013/S016

Edwards EVOQUE Transcatheter Tricuspid Valve Replacement System

Edwards Lifesciences, LLC · Decision date Aug 13, 2025

FDA DECISIONP230013/S016

What did the FDA approve?

FDA records P230013/S016 as a supplement to PMA P230013, with the supplement type “Normal 180 Day Track No User Fee”. The recorded decision is approval, dated Aug 13, 2025.

FDA approval order statement

approval to add the Edwards Singapore facility, located in Changi, Singapore, as a qualified manufacturing site for the EVOQUE valve component of the EVOQUE TTVR System
Regulatory pathway
PMA supplement
Supplement type
Normal 180 Day Track No User Fee
Clinical specialty
Cardiovascular
Decision date
Aug 13, 2025
FDA change category
Location Change - Manufacturer/Sterilizer/Packager/Supplier

FDA source record

Regulatory record facts

Identifier
P230013/S016
Regulatory pathway
PMA supplement
Product code
NPW
Decision code
APPR
Decision date
Aug 13, 2025
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Percutaneously Delivered Prostheses and Tricuspid Valves.

Product code
NPW
FDA device class
3

For the original device and its historical approval scope, see PMA P230013. Subsequent supplements may change the device or its indications.

FDA decision timeline

  1. P230013 · Original PMA

    Edwards EVOQUE Tricuspid Valve Replacement System

  2. P230013/S016 received

    Application receipt date recorded by FDA.

  3. P230013/S017 · Related supplement

    Edwards EVOQUE tricuspid delivery system

  4. P230013/S016 · FDA decision

    Normal 180 Day Track No User Fee

  5. P230013/S018 · Related supplement

    Edwards EVOQUE tricuspid delivery system

  6. P230013/S020 · Related supplement

    Edwards EVOQUE Tricuspid Valve Replacement System

  7. P230013/S013 · Related supplement

    Edwards EVOQUE Tricuspid Valve Replacement System

  8. P230013/S019 · Related supplement

    EVOQUE Tricuspid Valve Replacement System

  9. P230013/S021 · Related supplement

    Edwards EVOQUE Tricuspid Valve Replacement System

  10. P230013/S022 · Related supplement

    Edwards EVOQUE Loading System (9850LSA); Edwards EVOQUE Loading System and Trimmer (9850LSB)

  11. P230013/S023 · Related supplement

    Edwards EVOQUE Tricuspid Valve Replacement System (9850TDS)

  12. P230013/S024 · Related supplement

    Edwards EVOQUE Heart Valve (sizes 44mm, 46mm, 48mm, 52mm)

  13. P230013/S025 · Related supplement

    Edwards EVOQUE Tricuspid Valve Replacement System

  14. P230013/S026 · Related supplement

    EVOQUE Tricuspid Valve Replacement System

  15. P230013/S028 · Related supplement

    Edwards EVOQUE Loading System and Trimmer, Model 9850LSB

  16. P230013/S030 · Related supplement

    Edwards EVOQUE Tricuspid Valve Replacement System

  17. P230013/S031 · Related supplement

    EVOQUE Tricuspid Delivery System (9850TDS); EVOQUE dilator kit (9850DK)

  18. P230013/S032 · Related supplement

    Edwards EVOQUE Tricuspid Valve Replacement System

  19. P230013/S027 · Related supplement

    EVOQUE Tricuspid Valve Replacement System

  20. P230013/S029 · Related supplement

    Edwards EVOQUE Tricuspid Valve Replacement System

  21. P230013/S033 · Related supplement

    EVOQUE Tricuspid Valve Replacement System

  22. P230013/S034 · Related supplement

    Edwards EVOQUE Tricuspid Valve Replacement System (9850EV)

Timeline entries are records held by MedtechLedger for P230013. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P230013

Product / regulatory recordCompanyPathwayDecision dateSource
Edwards Lifesciences, LLCPMA approvalFeb 1, 2024FDA
Edwards Lifesciences, LLCPMA supplementJul 23, 2025FDA
Edwards Lifesciences, LLCPMA supplementSep 12, 2025FDA
Edwards Lifesciences, LLCPMA supplementSep 25, 2025FDA
Edwards Lifesciences, LLCPMA supplementOct 31, 2025FDA
Edwards Lifesciences, LLCPMA supplementNov 19, 2025FDA
Edwards Lifesciences, LLCPMA supplementFeb 2, 2026FDA
Edwards Lifesciences, LLCPMA supplementFeb 11, 2026FDA
Edwards Lifesciences, LLCPMA supplementFeb 12, 2026FDA
Edwards Lifesciences, LLCPMA supplementMar 11, 2026FDA
Edwards Lifesciences, LLCPMA supplementApr 10, 2026FDA
Edwards Lifesciences, LLCPMA supplementApr 16, 2026FDA
Edwards Lifesciences, LLCPMA supplementApr 29, 2026FDA
Edwards Lifesciences, LLCPMA supplementMay 26, 2026FDA
Edwards Lifesciences, LLCPMA supplementJul 29, 2026FDA
Edwards Lifesciences, LLCPMA supplementAug 5, 2026FDA
Edwards Lifesciences, LLCPMA supplementSep 16, 2026FDA
Edwards Lifesciences, LLCPMA supplementOct 19, 2026FDA
Edwards Lifesciences, LLCPMA supplementOct 21, 2026FDA
Edwards Lifesciences, LLCPMA supplementOct 28, 2026FDA

Explore the linked device profile

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Edwards Lifesciences, LLC

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
One Edwards Way, Irvine, CA, 92614

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records